Bizengri
Payments companies reported to CMS as associated with Bizengri. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Bizengri, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Bizengri
These are the largest totals companies reported as associated with Bizengri. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Rekha Abichandani | Cambridge, MA | Nephrology (Internal Medicine) | $273,900.00 |
| Jennifer Marks | Boston, MA | Medical Oncology | $9,146.00 |
| Wade Iams | Nashville, TN | Hematology & Oncology | $7,179.62 |
| Benjamin Weinberg | Washington, DC | Hematology & Oncology | $7,046.98 |
| Andrew Ko | San Francisco, CA | Medical Oncology | $6,532.61 |
| Gina Vaccaro | Cookeville, TN | Medical Oncology | $6,182.65 |
| Stacey Stein | New Haven, CT | Medical Oncology | $5,966.43 |
| Tejas Patil | Aurora, CO | Hospitalist | $5,795.87 |
| Richard Kim | Tampa, FL | Hematology & Oncology | $4,608.05 |
| Shirley Shiller | Nashville, TN | Anatomic Pathology & Clinical Pathology | $4,575.00 |
Prescribed Bizengri?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.